Biopharm News - BioPharm International

ADVERTISEMENT

Biopharm News
News from biopharmaceutical companies, including mergers, acquisitions, drug approvals, drug recalls.

EMA Recommended 81 Medicines for Marketing Authorization in 2013

January 23, 2014

In 2013, the EMA's Committee for Medicinal Products for Human Use recommended 81 medicines for human use for marketing authorization, compared with 57 in 2012.

Zymeworks, ImClone Systems to Develop Bi-specific Antibodies

January 9, 2014

Zymeworks has entered into a licensing and collaboration agreement with ImClone Systems to develop novel bi-specific antibody oncology therapeutics.

CytomX Therapeutics and ImmunoGen to Develop Probody-Drug Conjugates

January 9, 2014

CytomX Therapeutics and ImmunoGen announce collaboration to develop probody-drug conjugate therapies for the treatment of cancer.

Hemispherx Biopharma Reports Clinical Potential of Treatment for Drug-Resistant Influenza Virus

January 9, 2014

Research was published describing a natural interferon-alpha for infection control and treatment of drug-resistant H7N9 influenza.

Genzyme Receives Complete Response Letter from FDA on Lemtrada Application

December 31, 2013

Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.

Baxter Initiates Worldwide Voluntary Recall

December 30, 2013

Baxter International recalls dextrose injection and four sodium chloride injections.

Pfenex Awarded Anthrax Vaccine Contract

December 19, 2013

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

Nearly 400 Drugs in Development for Infectious Diseases

December 16, 2013

Almost 400 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections.

FDA Approves Extended-Release, Single-Entity Hydrocodone Product

October 28, 2013

Zhoydro ER is the first drug to have updated labeling now required for all ER/LA opioid analgesics.

ADVERTISEMENT

ADVERTISEMENT

Click here